DC Chemicals-Focus on Bioactive Chemicals

MORE>>Featured Products

Cat. No.	Product Name	Field of Application
DC67295	Lipid MK16 Featured	MK16 is a specialized lipid designed to traverse the blood-brain barrier (BBB) for effective mRNA delivery. Its formulation, MK16 BLNP, leverages dual mechanisms involving caveolae and γ-secretase to facilitate BBB penetration, ensuring the targeted and efficient transport of functional mRNA to diverse brain cell types. Demonstrating excellent tolerability across a range of dosing regimens, MK16 BLNP represents a promising platform for brain-targeted therapeutic applications.
DC67279	Rhobo6 Featured	Rhobo6 is a cell-impermeable small-molecule fluorophore designed for labeling the extracellular matrix (ECM) in live tissues. It contains a phenylboronic acid group that binds to diols commonly found in ECM glycans, resulting in a significant increase in fluorescence and a red shift in emission spectra. This property allows Rhobo6 to effectively visualize ECM architecture without perturbing native structures, making it suitable for long-term imaging studies. Additionally, Rhobo6's low affinity for monosaccharides enables reversible binding, which prevents photobleaching and allows for dynamic imaging of ECM components. While Rhobo6 does not specifically target individual ECM components, it provides a holistic view of ECM distribution and is particularly useful for studying ECM-related biological phenomena in samples that are not amenable to genetic manipulation or ex vivo culture.Rhobo6 is available under license from the Howard Hughes Medical Institute.
DC99010	Capstan lipid CICL-1(L829) Featured	Lipid CICL-1 s a novel ionizable cationic lipid used for tLNP(targeting antibody LNP) targeting to T cell,with pKa range 6-7, high encapsulation efficiency and high T cell transfection, compared to benchmark ATX-126 and other lipids. Lipid CICL-1 is an ionizable cationic lipid featuring a pentaerythritol core symmetrically esterified with four linear C9 alkyl chains (nonanoate esters) to ensure biodegradability. Its structure incorporates a tertiary amine headgroup (-N(CH₃)₂) linked via a short ethoxy spacer, enabling pH-dependent protonation (pKa ~6-7) for optimal nucleic acid encapsulation and endosomal escape. The tetra-branched architecture promotes a conical molecular shape, enhancing lipid nanoparticle (LNP) fusogenicity and cargo release efficiency. The C9 ester chains balance lipophilicity (cLogD ~11-14) for LNP stability while remaining susceptible to esterase hydrolysis, yielding non-toxic metabolites: nonanoic acid, butyrolactone derivatives, and polar diols for renal clearance. Designed to minimize hepatic accumulation, CICL-1’s ester cleavage sites avoid steric hindrance, enabling rapid biodegradation without generating reactive intermediates. Its structure optimizes transfection efficacy in targeted LNPs by maintaining neutral charge at physiological pH (reducing off-target interactions) while acquiring positive charge in acidic endosomes to disrupt membranes. This molecular design synergizes high nucleic acid payload capacity, low cytotoxicity, and metabolic safety for therapeutic applications.
DC60676	MRT6160 Featured	MRT-6160 represents a groundbreaking molecular glue degrader designed to selectively target VAV1, achieving its proteasomal degradation with a DC50 value of 7 nM. This innovative compound showcases its unique mechanism and therapeutic potential.
DC60636	Acid-degradable Cationic Lipid (ADC) Featured	Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.
DC60559	PT-179 Featured	PT-179 is a novel orthogonal immunomodulatory drug (IMiD) derivative that selectively binds to CRBN without inducing degradation of off-target proteins. It demonstrates potent activity in degrading proteins fused to SD40, regardless of whether the fusion occurs at the N or C terminus.
DC60518	ACBI3 Featured	ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).
DC60502	GalNAc Lipid GL6(GalNAc Lipid 1004) Featured	GL6 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a 36-unit PEG spacer, anchored by a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail. This structure balances ligand accessibility (via optimized PEG length) and nanoparticle stability (via hydrophobic DSG anchoring). Compared to GL3 (TRIS scaffold, same PEG length), GL6’s simplified lysine scaffold improves manufacturability. In LDLR-deficient models, GL6 enabled 61% liver editing (vs. 5% with standard LNPs) at 2 mg/kg, demonstrating superior ASGPR targeting. Its design minimizes ligand crowding (0.05 mol% surface density) while maximizing endosomal escape and durable gene editing.
DC60444	FX-909 Featured	FX-909（FX 909） is a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor with EC50 of 1 nM and shows >2000-fold selectivity for PPARG over PPARA/PPARD - acting through a mechanism that promotes a repressive conformation of PPARG.
DC72546	Tri-GalNAc-NHS ester Featured	Tri-GalNAc-NHS ester is a LYsosome TArgeting Chimera (LYTAC) and a ligand of asialoglycoprotein receptor (ASGPR). ASGPR is a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of extracellular proteins including membrane proteins. Tri-GalNAc-NHS ester can be used as a protein degrader and it can be used for the research of LYTAC.